Biodesix, Inc.
NASDAQ:BDSXMedical - Diagnostics & Research
+$2.04 today
- Market cap
- $68.38M
- Beta
- 0.59
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$3.31
Volume 0.17M
Average 0.06M
BDSX Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Biodesix, Inc.NASDAQ: BDSX
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt falls 88.9% from a year ago
Short-term debt stood at $2K at the end of Q1 FY2026, down 88.9% from a year earlier and down 66.7% from the prior quarter. Over 3 fiscal years it compounded at -50.3% a year.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -88.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 6K USD
- Year-over-year change
- -71.4%
- 4-year CAGR
- -25.0%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6K | -71.4% |
| FY2024 | 2024-12-31 | 21K | -58.8% |
| FY2023 | 2023-12-31 | 51K | +4.1% |
| FY2022 | 2022-12-31 | 49K | +157.9% |
| FY2021 | 2021-12-31 | 19K | — |
Short-term Debt vs competitors
How BDSX compares with its peers on the latest reported figures
- BDSX's Mar 2026 short-term debt of $2K is the 3rd highest of the 5 companies compared; the peer median is $352K.
- Its year-over-year change of -88.9% is the lowest of 2, against a peer median of -58.3%.
- Short-term debt amounts to 0.0% of total assets for BDSX, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.21M | -58.3% | — | 21.1% | |
| Mar 2026 | $704K | — | — | 2.7% | |
| Mar 2026 | $2K | -88.9% | -50.3% | 0.0% | |
OKUROnKure Therapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BDSX) | $352K | -58.3% | — | 1.4% | |
Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.71M | 43.09M | 26.28M | 26.25M | 18.99M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.66M | 5.07M | 7.68M | 8.6M | 9.04M |
| Inventory | 2.9M | 1.4M | 1.4M | 0 | 0 |
| Other Current Assets | 7.25M | 5.18M | 4.32M | 4.64M | 4.5M |
| Total Current Assets | 43.61M | 53.33M | 39.68M | 39.48M | 32.52M |
| Property, Plant & Equipment (Net) | 4.18M | 8.82M | 29.61M | 29.6M | 27.81M |
| Goodwill | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M |
| Intangible Assets | 11.62M | 9.8M | 7.91M | 5.87M | 3.88M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.66M | 5.92M | 6.86M | 7.26M | 8.23M |
| Total Non-current Assets | 32.48M | 39.57M | 59.41M | 57.76M | 54.96M |
| Total Assets | 76.1M | 92.91M | 99.1M | 97.24M | 87.48M |
| Account Payables | 1.66M | 1.69M | 2.93M | 2.19M | 3.08M |
| Short-term Debt | 19K | 49K | 51K | 21K | 6K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.85M | 962K | 324K | 678K | 961K |
| Other Current Liabilities | 21.4M | 15.05M | 26.01M | 792K | 8.83M |
| Total Current Liabilities | 28.96M | 22.84M | 33.42M | 14.32M | 17.44M |
| Long-term Debt | 9.99M | 25M | 35.23M | 36.41M | 47.45M |
| Deferred Tax Liabilities | 0 | (400K) | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 400K | 0 | 0 | 0 |
| Other Non-current Liabilities | 17.42M | 19.2M | 712K | 815K | 1.02M |
| Total Non-current Liabilities | 27.41M | 49.46M | 61.1M | 62.05M | 72.51M |
| Total Liabilities | 56.37M | 72.3M | 94.52M | 76.37M | 89.94M |
| Common Stock | 31K | 78K | 96K | 145K | 8K |
| Retained Earnings | (301.97M) | (367.42M) | (419.57M) | (462.5M) | (497.76M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 19.73M | 20.61M | 4.58M | 20.88M | (2.47M) |
| Total Debt | 10.01M | 31.85M | 60.69M | 61.98M | 72.85M |
| Net Debt | (22.7M) | (11.24M) | 34.41M | 35.73M | 53.87M |
Biodesix, Inc.
NASDAQ:BDSX
Intrinsic Alpha fair value
Locked
Current Price
$8.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.